{
    "nctId": "NCT00253539",
    "briefTitle": "Arzoxifene or Tamoxifen in Preventing Breast Cancer in Premenopausal Women at High Risk for Breast Cancer",
    "officialTitle": "A Phase II Study of a Selective Estrogen Receptor Modulator (LY353381) vs. Tamoxifen vs. Placebo in Premenopausal Women With and Increased Risk for Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2)",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 3,
    "primaryOutcomeMeasure": "Ki67 in breast tissue of enrolled patients",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Estimated probability of carrying a BRCA1 or BRCA2 mutation \u2265 10% AND meets one of the following criteria:\n\n  * Participants must have first-degree relatives (FDRs)\\* or second-degree relatives (SDRs)\\* (with an intervening male relative) with breast or ovarian cancer who satisfy one of the following criteria:\n\n    * High-risk breast/ovarian cancer (non-Jewish families)\n\n      * One FDR \u2264 40 years old\\*\\* diagnosed with breast cancer\n      * At least two FDRs or SDRs diagnosed with breast cancer at \u2264 50 years old OR had bilateral breast cancer\n      * One FDR or one SDR diagnosed with breast cancer at \u2264 50 years old OR had bilateral breast cancer AND one FDR or SDR diagnosed with ovarian cancer\n      * Three FDRs and/or SDRs diagnosed with breast or ovarian cancer (at least one in case of ovarian cancer)\n      * Two FDRs and/or SDRs diagnosed with ovarian cancer\n      * One male FDR or SDR diagnosed with breast cancer and one FDR or SDR (male or female) diagnosed with breast or ovarian cancer\n    * Moderate-risk breast /ovarian cancer (non-Jewish families)\n\n      * Two FDRs diagnosed with breast cancer with one \u2264 50 years old and/or both \\< 60 years old\n      * One FDR and one SDR (mother or sister and maternal aunt or maternal grandmother) diagnosed with breast cancer if the sum of their ages is \u2265 118 years\n      * One FDR and one SDR (mother or sister and paternal aunt or paternal grandmother) diagnosed with breast cancer if the sum of their ages is \u2265 78 years\n      * Two SDRs (both maternal or both paternal) diagnosed with breast cancer if the sum of their ages is \u2264 98 years\n      * One FDR with ovarian cancer\n    * High-risk breast/ovarian cancer (Jewish families )\n\n      * At least one FDR or SDR diagnosed with breast cancer at \u2264 50 years old\n      * At least one FDR or SDR diagnosed with ovarian cancer\n      * At least one FDR or SDR diagnosed with breast cancer at any age AND one FDR or SDR diagnosed with breast and/or ovarian cancer\n      * At least one male FDR or SDR diagnosed with breast cancer NOTE: \\*FDRs are parents, siblings, and children of the participant; SDRs are aunts, uncles, grandparents, grandchildren, nieces, nephews, or half siblings of the participant\n\nNOTE: \\*\\*Age is approximated to the earliest age possible (e.g., a relative diagnosed in their 40's should be considered 40)\n\n* Patterns of cancer cases must all be on the maternal or paternal side of the family\n* Participants not meeting any of the above FDR or SDR criteria may provide medical documentation stating that they, a FDR, or a SDR carry BRCA1 or BRCA2 mutations\n\n  * Participants with a prior history of breast cancer are eligible provided they have a remaining breast that has not been irradiated, all therapy for breast cancer was completed more than 2 years ago, and they are premenopausal\n  * No ovarian cyst during screening\n  * No more than 12 months since prior Pap smear with normal cytological results OR human papilloma virus negative if atypical squamous cells of uncertain significance (ASCUS) present\n* No higher degrees of atypia beyond ASCUS on Pap smear\n\n  * No known history of osteoporosis (bone mineral density \\> 1.5 standard deviations below young adult norms)\n  * Hormone receptor status\n* Not specified\n\nPATIENT CHARACTERISTICS:\n\nMenopausal status\n\n* Premenopausal, as defined by 1 of the following:\n\n  * Last menstrual period \\< 6 months ago\n  * Less than 45 years old AND underwent partial hysterectomy OR follicle-stimulating hormone within institutional pre-menopausal range within the past 3 months\n\nSex\n\n* Female\n\nPerformance status\n\n* ECOG 0-1\n\nLife expectancy\n\n* More than 2 years\n\nHematopoietic\n\n* WBC \u2265 3,000/mm\\^3\n* Platelet count \u2265 125,000/mm\\^3\n* Hemoglobin \u2265 10 g/dL\n\nHepatic\n\n* Bilirubin \u2264 1.5 mg/dL\n* AST \\< 2 times upper limit of normal (ULN)\n* Albumin \u2265 3.0 g/dL\n* PT/PTT \u2264 1.25 times ULN\n\nRenal\n\n* Creatinine \u2264 1.5 mg/dL OR\n* Creatinine clearance \u2265 60 mL/min\n\nCardiovascular\n\n* No history of deep venous thrombosis\n\nPulmonary\n\n* No history of pulmonary embolism\n\nOther\n\n* Not pregnant or nursing\n* Negative pregnancy test\n* Fertile participants must use effective barrier-method contraception during and for 3 months after completion of study treatment\n* No other malignancy within the past 2 years except curatively treated basal cell or squamous cell skin cancer or cervical cancer \u2264 stage I\n* No known addiction\n* Not undergoing treatment for an illicit drug addiction\n* Willing and able to undergo required study procedures (e.g., research-related breast biopsies)\n\nPRIOR CONCURRENT THERAPY:\n\nChemotherapy\n\n* More than 2 years since prior chemotherapy\n\nEndocrine Therapy\n\n* At least 3 months since prior oral contraceptives or intramuscular progestational agent\n* At least 3 months since prior luteinizing-hormone releasing hormone (LHRH) agonists or antagonists if agent was administered daily or monthly\n* At least 6 months since prior LHRH agonists or antagonists if agent was administered every 3 months\n* At least 6 months since prior antiestrogens (e.g., tamoxifen, toremifene, and raloxifene)\n* No concurrent progestational or contraceptive agents\n\nRadiotherapy\n\n* See Disease Characteristics\n* More than 2 years since prior radiotherapy\n\nSurgery\n\n* No prior prophylactic bilateral mastectomy\n\nOther\n\n* No concurrent cholestyramine\n* No concurrent routine warfarin, bromocriptine, or phenobarbital\n* No other concurrent investigational agents",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}